The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001

E Trias, M Juan, A Urbano-Ispizua… - Bone Marrow …, 2022 - nature.com
Abstract In February 2021, the 'Advanced Therapy Medicinal Product'(ATMP) ARI-0001
(CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization …

[HTML][HTML] Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review

AR Dos Santos, D Zanini, D Andolfatto - Hematology, Transfusion and Cell …, 2024 - Elsevier
Introduction Chimeric antigen receptor T (CAR-T) cell therapy is an innovative technology
that has shown promising results in clinical trials. Treatment is based on modifying the …

Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond.

P Khodke, BV Kumbhar - Advances in Protein Chemistry and …, 2024 - europepmc.org
Chimeric Antigen Receptor (CAR) T cell therapy is a type of adoptive immunotherapy that
offers a promising avenue for enhancing cancer treatment since traditional cancer …

[PDF][PDF] The role of anti-apoptotic c-FLIP in CAR-T cells targeting solid tumours

GMY Tan - 2021 - ourarchive.otago.ac.nz
Chimeric antigen receptor (CAR) T-cell therapy has recently emerged as a promising
treatment for targeting haematological malignancies, however, this treatment of solid …

[HTML][HTML] Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

K Kızılbey, N Türkoğlu, FC Kırmızıtaş - Cell Interaction-Molecular …, 2020 - intechopen.com
Cancer immunotherapy is based on the idea of overcoming the main problems in the
traditional cancer treatments and enhancing the patient's long-term survival and quality of …